🇺🇸 concomitant therapy in United States
2 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 2
Most-reported reactions
- Leukopenia — 1 report (50%)
- Thrombocytopenia — 1 report (50%)
Frequently asked questions
Is concomitant therapy approved in United States?
concomitant therapy does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for concomitant therapy in United States?
Ying HUANG is the originator. The local marketing authorisation holder may differ — check the official source linked above.